Clinical Impact of Tumour DNA Repair Expression and T-cell Infiltration in Breast Cancers

Green, Andrew R., Aleskandarany, Mohammed A. orcid iconORCID: 0000-0001-5538-5946, Ali, Reem, Hodgson, Eleanor Grace, Atabani, Suha, De Souza, Karen, Rakha, Emad A., Ellis, Ian O. and Madhusudan, Srinivasan (2017) Clinical Impact of Tumour DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunology Research, 5 (4). pp. 292-299. ISSN 2326-6066

[thumbnail of Author Accepted Manuscript]
PDF (Author Accepted Manuscript) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.


Official URL:


Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We investigated the expression of proteins involved in the DNA damage response (ATM, Chk2), double-strand break repair (BRCA1, BLM, WRN, RECQL4, RECQL5, TOPO2A, DNA-PKcs, Ku70/Ku80), nucleotide excision repair (ERCC1), base excision repair (XRCC1, pol β, FEN1, PARP1), and immune responses (CD8, PD-1, PD-L1, FOXP3) in 1,269 breast cancers and validated our findings in an independent estrogen receptor–negative (ER−) cohort (n = 279). Patients with tumors that expressed low XRCC1, low ATM, and low BRCA1 were not only associated with high numbers of CD8+ tumor-infiltrating lymphocytes, but were also linked to higher grades, high proliferation indexes, presence of dedifferentiated cells, ER− cells, and poor survival (all P ≤ 0.01). PD-1+ or PD-L1+ breast cancers with low XRCC1 were also linked to an aggressive phenotype that was high grade, had high proliferation indexes, contained dedifferentiated cells and ER− (all with P values ≤ 0.01), and poor survival (P = 0.00021 and P = 0.00022, for PD-1+ and PD-L1+ cancers, respectively) including in an independent ER− validation cohort (P = 0.007 and P = 0.047, respectively). We conclude that the interplay between DNA repair, CD8, PD-L1, and PD-1 can promote aggressive tumor phenotypes. XRCC1-directed personalization of immune checkpoint inhibitor therapy may be feasible and warrants further investigation in breast cancer. Cancer Immunol Res; 5(4); 292–9. ©2017 AACR.

Repository Staff Only: item control page